Search
Powered By HealthLine
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

A Lifesaving Chill for Cardiac Arrest

Ivanhoe Broadcast News


(Ivanhoe Newswire) -- Rapidly cooling a heart attack victim could help save his or her life and prevent him or her from suffering brain damage.

In an effort to reduce injury, the practice of cooling patients after cardiac arrest has been performed for years; but now there's a way to cool patients right after they suffer an event -- a critical period of time.

Text Continues Below



RhinoChill is a new tool that cools the brain during ongoing cardiopulmonary resuscitation (CPR). It is a battery-operated, non-invasive device that works by delivering coolant through nasal prongs.

In a recent study, 200 adults who were witnessed into going into cardiac arrest were administered either standard resuscitation or treatment with the RhinoChill. Eighteen of the patients were excluded from the research because of a "do not resuscitate" order or because there was a non-cardiac cause of their cardiac arrest.

For patients receiving the cooling therapy, cooling began a median of 23 minutes after their cardiac arrest. Results showed 46.7 percent of those who received the RhinoChill survived to hospital discharge, compared with 31 percent of those receiving standard care. Upon discharge, 36.7 percent of those cooled were in good neurological condition, compared with 21.4 percent of those given standard care. Results were even better for patients whose cooling therapy began within ten minutes of cardiac arrest: 59.1 percent survived to hospital discharge, and 45.5 percent were neurologically intact upon discharge.

"RhinoChill is easy and safe to use during a cardiac arrest outside of the hospital," Denise Barbut, M.D., senior author of the study and president and chairman of BeneChill, Inc., maker of the device, was quoted as saying. "Although the study was not powered to look at outcomes, there seemed to be a significant benefit on survival and neurologically intact survival, specifically in those treated within ten minutes."

Some adverse reactions reported from the RhinoChill include nosebleeds, nasal discolorations, seizure, and repeat cardiac arrest.

Source: American Heart Association's Scientific Sessions, November 14-18, 2009, Orlando, FL



If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Melissa Medalie at mmedalie@ivanhoe.com

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.




Last updated 11/17/2009

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake





HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2012. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire